Organ response assessment (ITT)
| . | Responders* . | Nonresponders† . | Deaths‡ . | Missing/alive§ . |
|---|---|---|---|---|
| DD | ||||
| Cardiac 3 mo | 10% (7) | 51% (37) | 10% (7) | 30% (22) |
| Cardiac 6 mo | 22% (15) | 35% (24) | 22% (15) | 21% (14) |
| Cardiac 12 mo | 18% (11) | 31% (19) | 33% (20) | 18% (11) |
| Renal 3 mo | 20% (9) | 45% (20) | 2% (1) | 32% (14) |
| Renal 6 mo | 24% (10) | 38% (16) | 10% (4) | 29% (12) |
| Renal 12 mo | 14% (5) | 51% (18) | 26% (9) | 9% (3) |
| DVD | ||||
| Cardiac 3 mo | 28% (13) | 48% (22) | 13% (6) | 11% (5) |
| Cardiac 6 mo | 26% (11) | 44% (19) | 19% (8) | 12% (5) |
| Cardiac 12 mo | 25% (9) | 39% (14) | 28% (10) | 8% (3) |
| Renal 3 mo | 10% (3) | 56% (18) | 3% (1) | 31% (10) |
| Renal 6 mo | 24% (7) | 41% (12) | 7% (2) | 28% (8) |
| Renal 12 mo | 27% (7) | 42% (11) | 27% (7) | 4% (1) |
| . | Responders* . | Nonresponders† . | Deaths‡ . | Missing/alive§ . |
|---|---|---|---|---|
| DD | ||||
| Cardiac 3 mo | 10% (7) | 51% (37) | 10% (7) | 30% (22) |
| Cardiac 6 mo | 22% (15) | 35% (24) | 22% (15) | 21% (14) |
| Cardiac 12 mo | 18% (11) | 31% (19) | 33% (20) | 18% (11) |
| Renal 3 mo | 20% (9) | 45% (20) | 2% (1) | 32% (14) |
| Renal 6 mo | 24% (10) | 38% (16) | 10% (4) | 29% (12) |
| Renal 12 mo | 14% (5) | 51% (18) | 26% (9) | 9% (3) |
| DVD | ||||
| Cardiac 3 mo | 28% (13) | 48% (22) | 13% (6) | 11% (5) |
| Cardiac 6 mo | 26% (11) | 44% (19) | 19% (8) | 12% (5) |
| Cardiac 12 mo | 25% (9) | 39% (14) | 28% (10) | 8% (3) |
| Renal 3 mo | 10% (3) | 56% (18) | 3% (1) | 31% (10) |
| Renal 6 mo | 24% (7) | 41% (12) | 7% (2) | 28% (8) |
| Renal 12 mo | 27% (7) | 42% (11) | 27% (7) | 4% (1) |
Percentages with numbers in parentheses. Percentages at 3 months were calculated for 73 cardiac and 44 renal response assessable patients receiving DD and for 46 cardiac and 32 renal response assessable patients receiving DVD. Percentages at 6 months were calculated for 68 cardiac and 42 renal response assessable patients receiving DD and for 43 cardiac and 29 renal response assessable patients receiving DVD. Percentages at 12 months were calculated for 61 cardiac and 35 renal response assessable patients receiving DD and for 36 cardiac and 26 renal response assessable patients receiving DVD.
NT-ProBNP decrease of at least 30% and ≥300 ng/L measured at 3, 6, and 12 months compared with start of daratumumab for cardiac responders or decrease of proteinuria by ≥30% or <0.5 g/d without renal progression for renal responders.
NT-ProBNP assessed at 3, 6, and 12 months not fulfilling cardiac response criteria or proteinuria and eGFR assessed at landmark not fulfilling renal response criteria.
Patients fulfilling organ response eligibility criteria at start of daratumumab dead at 3, 6, and 12 months.
Patients fulfilling organ response eligibility criteria at start of daratumumab alive at 3, 6, and 12 months not assessed for organ response.